AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 3 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 10 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 30 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 45 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 60 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 90 mg, Once Daily, 14 days
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-866949
Description: Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
Study NCT02475941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Weight bearing
Description: The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.
Study NCT02475941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Weight Bearing
Description: The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient.
Study NCT00000408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient education evaluation
Study NCT01527617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry
Description: beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
Study NCT01527617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Cranberry beverage
Description: Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
Study NCT02483832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
Study NCT02005887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
Study NCT02005887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
Study NCT02005887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg orally every day for 6 cycles
Study NCT00074776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.
Study NCT00074776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Participants will receive lamotrigine.
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 3mg/kg iv every 28 days for 3 infusions
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20mg/kg iv every 28 days for 3 infusions
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 7mg/kg iv every 28 days for 3 infusions
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3mg/kg iv every 28 days for 3 infusions
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7mg/kg iv every 28 days for 3 infusions
Study NCT03674671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
Study NCT00760565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20mg/kg iv every 28 days for 3 infusions
Study NCT00792870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
Study NCT00792870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
Study NCT01647672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane for neoadjuvant chemotherapy
Study NCT03120533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iontophoresis of treprostinil
Description: the participant will receive 10 days of iontophoresis of treprostinil on a first site
Study NCT03120533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis of placebo
Description: the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
Study NCT02991027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI OCT Triton
Description: DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
Study NCT02991027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI OCT Triton
Description: DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
Study NCT04264923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HyGIeaCare Prep
Description: Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
Study NCT02615977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zooming Joystick Task
Description: Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.
Study NCT02615977 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Zooming Joystick Task (Placebo)
Description: Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates.
Study NCT03674671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
Study NCT03214185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF/ICSI
Description: in vitro fertilization or intracytoplasmatic sperm injection
Study NCT03214185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: in vitro fertilization or intracytoplasmatic sperm injection
Study NCT03214185 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGS 2.0
Description: Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
Study NCT03214185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional embryo morphology evaluation
Description: Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
Study NCT04611932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D090 Tab.
Description: 1T
Study NCT04611932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T
Study NCT03196882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg/day of iron
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
Study NCT03196882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg/day of iron
Description: Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
Study NCT01898325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Fibroscan
Study NCT02789462 — intervention group
Intervention type: PROCEDURE
Intervention: Laser-assisted percutaneous coronary interventions
Description: Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
Study NCT03856463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Navigator Intervention
Description: Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
Study NCT03856463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT03856463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT03911856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
Study NCT03911856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Gas Exchange
Description: We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
Study NCT03000218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic acid 300mg bid for 8 weeks
Study NCT03000218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Day 29 to 56: Metformin 500mg bid
Study NCT03000218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to 56: Placebo bid
Study NCT00516009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXAMETHASONE
Study NCT00516009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT03254030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic inspection
Description: Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
Study NCT03254030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colonic inspection
Description: Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
Study NCT03728218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses (Orthokeratology)
Description: Contact lenses
Study NCT03728218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses (Soft Multifocal)
Description: Contact lenses
Study NCT00729274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline solution
Description: Two 4ml nebulizations with 30 minute interval
Study NCT00729274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution
Description: Two 4ml nebulizations with 30 minute interval
Study NCT02459496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting and advise
Description: first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
Study NCT03760250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
Study NCT03982472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electric stimulation
Description: transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
Study NCT03530176 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18Fluoride-Sodium Fluoride radio-isotope
Description: The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
Study NCT02011113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
Study NCT02011113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
Study NCT01102062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange juice
Study NCT01206114 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Questionnaires, interviews, nasal/oral and serum samples, register data
Study NCT00706095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
Study NCT00706095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
Study NCT00706095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
Study NCT02129296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air filled balloon
Description: Balloon filled with air according to the manufacturing company orders
Study NCT02129296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioenteric BIB® balloon
Description: Balloon filled with saline and methylene blue according to the manufacturing company orders
Study NCT03814616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine tetraphosphate 180mg:artesunate 60mg
Description: ACT
Study NCT03196882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg/day of iron
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
Study NCT02488330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
Study NCT02488330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
Study NCT02488330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
Study NCT03702361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPRIV
Description: VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Study NCT03880916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Study NCT03880916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Study NCT03880916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Study NCT03880916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Study NCT00787397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Sleep
Description: Cognitive Behavioral Therapy: 6 sessions of CBT
Study NCT00522782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Budesonide
Description: Pulmicort Respules 0.5mg/2cc
Study NCT00522782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide Analyzer
Description: Niox NO analyzer
Study NCT02733081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified IUD Insertion
Description: IUD Insertion with no bimanual pelvic exam or uterine sounding.
Study NCT02553928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (once daily)
Study NCT02553928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (twice daily)
Study NCT01885650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway Clearance Techniques
Study NCT02376244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
Study NCT04188249 — intervention group
Intervention type: DRUG
Intervention: Golimumab
Description: This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.